Current Progress and Research Trends in Ocular Oncology

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue with an original article or review in the field of ocular oncology with a focus on uveal melanoma, conjunctival melanoma or retinoblastoma. Uveal melanoma and retinoblastoma, which cause blindness and even death, are the most common primary intraocular malignancies in adults and children, respectively. Conjunctival melanoma shares genetic and pathophysiological features with cutaneous melanomas and is distinct from uveal melanoma. Although our understanding of these ocular cancers has advanced over the last decade and local tumor control is mostly achievable, they remain malignancies with recurrence and no treatment for metastatic disease.

This Special Issue aims to highlight current progress and research trends in all aspects of ocular oncology, including oncogenic pathways and genetic and cellular heterogeneity, and cancer immunity that underlie the initiation, progression, recurrence and metastasis of ocular tumors. Basic science studies with translational aspects as well as clinical trials are strongly encouraged. Experts in the field are invited to contribute with articles reviewing the latest perspectives in ocular cancer biology or diagnosis and therapy. This Special Issue reflects the wide range of efforts to advance the understanding and treatment of eye cancers.

Prof. Dr. Utta Berchner-Pfannschmidt
Dr. Miltiadis Fiorentzis
Prof. Dr. Nikolaos E. Bechrakis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.